We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MALLPLAZA:BCSPlaza SA Analysis

Data as of 2026-03-12 - not real-time

CLP 3,811.10

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Plaza S.A. posted a robust 23.6% YoY revenue increase in Q4 2025 and a 32.2% jump for the full year, with EBITDA climbing 30.2% – a clear sign that the core business is accelerating. The company’s PE ratio of 5.8 is dramatically below the industry average of 32.6, while its price‑to‑book of 1.86 reflects a modest premium to net assets. Revenue growth of 22.7% and an operating margin north of 80% underscore strong operational leverage, and a dividend yield of 2.07% with a payout ratio under 8% points to a sustainable income stream. However, the balance sheet is heavily leveraged, with a debt‑to‑equity ratio of 35.3 and total debt far exceeding cash reserves, which tempers the upside. Technicals show the stock trading just above the 50‑day SMA (3,762) but below the 20‑day SMA (3,929), a bearish MACD histogram and declining volume suggest short‑term pressure, while the overall trend remains bullish. Volatility is high at 47% over the past 30 days, but a low beta of 0.21 indicates limited market‑wide risk exposure.
Given the cheap valuation, strong cash generation (free cash flow of 326 B CLP), and a dividend that appears well‑covered, the medium‑ to long‑term outlook is positive, especially if the company can deleverage over time. Analyst sentiment leans “buy,” though consensus target prices (3,481‑3,600) sit below the current level of 3,811, hinting at a potential pull‑back toward support around 3,624. The extreme greed reading (78) reflects bullish market mood, but investors should watch for any signs of debt stress or macro‑economic headwinds in Chile, Colombia, and Peru.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price approaching near‑term support at 3,624 CLP
  • Bearish MACD histogram and decreasing volume
  • Neutral RSI around 47 indicating limited momentum

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Strong revenue and EBITDA growth from FY2025 earnings
  • Significantly low PE relative to industry peers
  • Sustainable dividend with low payout ratio

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • High ROE (37%) and solid free cash flow generation
  • Undervalued DCF fair value estimate (~4,580 CLP)
  • Potential deleveraging as cash flow improves

Key Metrics & Analysis

Financial Health

Revenue Growth22.70%
Profit Margin218.84%
P/E Ratio5.8
ROE37.35%
ROA4.84%
Debt/Equity35.33
P/B Ratio1.9
Op. Cash FlowCLP441.1B
Free Cash FlowCLP325.8B
Industry P/E32.6

Technical Analysis

TrendBullish
RSI47.3
SupportCLP 3,623.90
ResistanceCLP 4,370.00
MA 20CLP 3,928.93
MA 50CLP 3,762.92
MA 200CLP 2,815.27
MACDBearish
VolumeDecreasing
Fear & Greed Index78.16

Valuation

Fair ValueCLP 4,580.32
Target PriceCLP 3,481.00
Upside/Downside-8.66%
GradeUndervalued
TypeBlend
Dividend Yield2.07%

Risk Assessment

Beta0.21
Volatility47.09%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.